Intellia Therapeutics Newsroom

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers

Yahoo FinanceDec 11 11:57 ET

Lilly Tops Morgan Stanley's Biopharma Pick List for 2025

Seeking AlphaDec 6 16:21 ET

Express News | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 3 16:01 ET

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireDec 3 16:01 ET

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

BenzingaNov 26 22:37 ET

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy

Zacks Nov 26 10:05 ET

JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsNov 26 06:31 ET · Ratings

Promising Outlook for Intellia Therapeutics' Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest

TipRanksNov 26 06:17 ET

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

MT NewswiresNov 25 13:45 ET

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation

MT NewswiresNov 25 11:02 ET

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

BenzingaNov 25 07:32 ET

Express News | Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Hereditary Transthyretin (Attr) Amyloidosis With Polyneuropathy

ReutersNov 25 07:30 ET

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (Nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis With Polyneuropathy

Intellia TherapeuticsNov 25 00:00 ET

Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby

Seeking AlphaNov 23 08:26 ET

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Yahoo FinanceNov 22 08:30 ET

Cathie Wood's ARK Investment Buys 223.5K Shares of Intellia Therapeutics Today

TipRanksNov 19 20:15 ET

A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $60 to $90

Moomoo NewsNov 19 08:00 ET · Ratings

Positive Buy Rating for Intellia Therapeutics Amid Promising Trial Results for Nex-z in ATTR-CM

TipRanksNov 19 06:55 ET · Ratings

Intellia Therapeutics Price Target Lowered to $70 From $80 at Wells Fargo

Yahoo FinanceNov 19 06:30 ET

Intellia Therapeutics' NTLA-2001 Shows Promising Potential With Positive Phase 1 Data and Accelerated Phase 3 Enrollment

TipRanksNov 19 01:56 ET